NEW YORK CITY, NY / ACCESS Newswire / January 4, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Perrigo Company plc ("Perrigo" or the "Company") (NYSE:PRGO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are […]

NEW YORK CITY, NY / ACCESS Newswire / January 4, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Unicycive Therapeutics, Inc. ("Unicycive" or "the Company") (NASDAQ:UNCY). Investors who purchased Unicycive securities prior to March 29, 2024, and continue to hold to the present, are encouraged to obtain

NEW YORK CITY, NY / ACCESS Newswire / January 4, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sun Communities, Inc. ("Sun Communities" or "the Company") (NYSE:SUI). Investors who purchased Sun Communities securities prior to February 28, 2019, and continue to hold to the present, are encouraged

NEW YORK CITY, NY / ACCESS Newswire / January 4, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Acadia Healthcare Company, Inc. ("Acadia Healthcare" or "the Company") (NASDAQ:ACHC). Investors who purchased Acadia Healthcare securities prior to February 28, 2020, and continue to hold to the present, are

NEW YORK CITY, NY / ACCESS Newswire / January 4, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Methode Electronics, Inc. ("Methode Electronics" or "the Company") (NYSE:MEI). Investors who purchased Methode Electronics securities prior to December 2, 2021, and continue to hold to the present, are encouraged

NEW YORK CITY, NY / ACCESS Newswire / January 4, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Telix Pharmaceuticals Limited ("Telix" or the "Company") (NASDAQ:TLX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are

LOS ANGELES, Jan. 04, 2026 (GLOBE NEWSWIRE) — Happy New Year! As 2026 begins, Nework extends warm wishes to customers, educators, partners, and technology enthusiasts everywhere. We sincerely thank you for your support in 2025–a year full of innovation, awards, and meaningful connections with our users. 2025 Highlights and Achievements In 2025, Nework strengthened its

Nework Celebrates Award-Winning 2025 and Looks Ahead to Smarter, Mobile Collaboration in 2026 Wishing everyone a prosperous new year, while continuing to empower home, education, and business users with innovative technology GlobeNewswire January 04, 2026 LOS ANGELES, Jan. 04, 2026 (GLOBE NEWSWIRE) — Happy New Year! As 2026 begins, Nework extends warm wishes to customers,

NEW YORK, NY / ACCESS Newswire / January 4, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Freeport-McMoRan Inc. (NYSE:FCX) securities. If you suffered a loss on your Freeport-McMoRan Inc. investment and would like to explore a potential

NEW YORK, NY / ACCESS Newswire / January 4, 2026 / Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. ("LENZ" or the "Company") (NASDAQ:LENZ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether LENZ and certain of its officers and/or directors